HomeBUSINESS
BUSINESS

Solifenacin Oral Suspension Approved in Europe for Pediatric NDO: Astellas
(Mar.12.2018)

Astellas Pharma said on March 9 that solifenacin oral suspension was approved in Europe for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 2 to 18 years ...
(LOG IN FOR FULL STORY)

News Calendar